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Identification of IG-clonality status as a 
pre-treatment predictor for mortality in patients
with immunodeficiency-associated Epstein-Barr
virus-related lymphoproliferative disorders
Immunodeficiency-associated Epstein-Barr (EBV)-related
lymphoproliferative disorders (EBV-LPD), including the
post-transplant lymphoproliferative disorders (PTLD), are
aggressive hematologic malignancies which, despite
improvements in therapy, including the use of anti-CD20
monoclonal antibody, result in considerable morbidity and
mortality.1-3 Retrospective analyses have revealed several
clinical risk factors, including therapeutic interventions,
that predict outcome in patients with EBV-LPD. However,
pre-treatment risk stratification that can be used to guide
therapeutic decisions remains difficult and algorithms are
lacking.1 Although morphology is regarded to be a corner-
stone in therapy decision making, immunoglobulin (IG)
clonality might help prognostication. Despite efforts to
standardize the pathological classification of EBV-LPD,4 nei-
ther histology nor IG clonality has been shown to consis-
tently predict outcome.5-7 Nevertheless, comprehensive IG
clonality testing, with a high detection rate of clonality,
allows an objective pathological parameter to be re-evalu-
ated in risk stratification of  EBV-LPD.8
We performed a retrospective analysis in a large multi-
center cohort of 86 patients with EBV-LPD: 62 patients
with an EBV-positive PTLD and 24 with another iatrogenic
immunodeficiency related EBV-LPD. Patients from 2000-
2012 were included in the analysis; patients’ characteristics
are presented in Online Supplementary Table S1. IG-gene
clonality testing was performed by assessment of the IGH-
V(D)J, -DJ as well as IGK (VJ and KDE) rearrangements
using the BIOMED2 approach. This IG clonality assay has
an unprecedented high detection rate8,9 due to the comple-
mentarity of the PCR- targets with a sensitivity of each
individual PCR of 5%-10% and the specificity of the IG-
clonality assay of 94%.10 In this study cohort, 20% of the
clonal cases had clonal IGK and/or incomplete IGH-DJ
rearrangements without having clonal IGH V(D)J-FR1, 2 or
3 rearrangements. These cases were found in both the EBV-
positive PTLD and the iatrogenic immunodeficiency-relat-
ed EBV-LPD group, and would have gone unnoticed when
clonality testing was based only on assessment of the com-
plete IGH rearrangement. Interpretation of the clonality
findings was performed according to the EuroClonality
guidelines.11 Patients were classified as having either mon-
oclonal or oligo/polyclonal EBV-LPD. Histology was exam-
ined by 2 experienced hematopathologists and designated
either monomorphous or reactive/polymorphous (no
Burkitt-or Hodgkin-type lesion was included) according to
the WHO criteria.4 In the majority of the cases, IG clonality
was detected in multiple PCRs. There was no clear differ-
ence in clonality pattern in monomorphic subtype PTLDs
versus the reactive/polymorphic PTLDs, albeit the last
group tended to have more cases showing monoclonality
with a polyclonal background, although this is not exclu-
sively seen in this group. A statistical analysis was per-
formed to identify pre-treatment risk factors for poor out-
come defined as EBV-LPD-related mortality, with an
emphasis on pathological features, but also clinical stage
according to Ann Arbor, extra-nodal disease, age and
underlying diagnosis. 
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Table 1. Univariable and multivariable analysis of risk factors for EBV-LPD related mortality.
Risk factor EBV-LPD OR P OR P
mortality univariable univariable multivariable multivariable
(95%CI) (95%CI)
Age
≥ 50 years 13/36 (36%) 2.6 (1.0-6.9) 0.08 3.6 (1.2-11)2 0.03
< 50 years 9/50 (18%)
Sex
Male 17/55 (31%) 2.3 (0.8-7.1) 0.2 - -
Female 5/31 (16%)
Diagnosis
PTLD 20/62 (32%) 5.2 (1.1-24.5) 0.03 1.5 (0.3-8.7)1 0.6
Iatrogenic EBV-LPD 2/24 (8%)
Stage
II-IV 21/59 (36%) 14.4 (1.8-113.5) 0.001 13.8 (1.6-117.2)2 0.02
I 1/27 (4%)
Extranodal disease
Yes 12/46 (26%) 1.1 (0.4-2.8) 1.0 - -
No 10/40 (25%)
Morphology
Monomorphic 15/45 (33%) 2.5 (0.9-6.8) 0.14 - -
Reactive/polymorphic 7/41 (17%)
IG clonality2
Monoclonal 21/66 (32%) 8.9 (1.1-70.7) 0.02 6.6 (0.8-59.1)2 0.09
Oligo/polyclonal 1/20 (5%)
EBV load at diagnosis3
≥ log 3 17/45 (38%) 1.5 (0.5-4.3) 0.5
< log 3 3/12 (25%
P < 0.05 was considered statistically significant. OR: odds ratio. 1Model with four covariates. 2Model with three covariates. 3Data on EBV load only present in 57 patients. 
Univariable analysis using the Fisher exact test revealed
multiple risk factors for EBV-LPD-related mortality; P<0.05
was considered significant (Table 1). This included PTLD as
underlying diagnosis, disease stage II-IV and IG monoclon-
ality, but not age 50 years or over, EBV load at diagnosis,
and monomorphic histology. Next we performed a multi-
variable logistic regression analysis with the four variables
having at least a P value of 0.10 in the univariable analysis.
In the first model, incorporating all four risk factors, under-
lying diagnosis was not associated with EBV-LPD-related
mortality (P=0.6), but the other three, including age 50
years or over, showed an association with P≤0.1. Analyzing
these three risk factors simultaneously in a second model
revealed that age and disease stage were significantly relat-
ed to EBV-LPD-related mortality (Table 1), and that IG-
clonality showed a trend (P=0.09). Nevertheless, the high
odds ratios at least suggest that the risk factors might all
have had an impact and that significance was not estab-
lished in all three of them due to the small cohort size.
Because diseases with a high mortality rate require prog-
nostic factors that preferably identify all those at risk for
mortality, we next investigated which of the pathological
factors had the highest sensitivity and negative-predictive
value for EBV-LPD-related mortality. Sensitivity, specificity,
negative predictive and positive predictive value for EBV-
LPD-related mortality in the total cohort were 68%, 53%,
83%, 33% for monomorphic morphology and 95%, 30%,
95%, 32% for monoclonal IG-gene status, respectively.
When looking at PTLD cases separately, similar results
were seen with the sensitivity and negative predictive value
of monoclonal IG-gene status exceeding that of monomor-
phic morphology (95% and 89% vs. 70% and 74%, respec-
tively).
The higher negative predictive value at least suggests that
IG-clonality testing performs better than histological exam-
ination when used to identify patients that are not at high
risk of death. So, patients can be identified that might not
require prompt treatment, that is, those with oligo/poly-
clonal disease. Clonality testing, however, has a similar, but
equally low, positive predictive value as histology.
Therefore, establishing either monoclonality or monomor-
phic disease does not necessarily mean that a patient is at
high risk for death from EBV-LPD, and therapeutic decision
making based on clonality status alone might result in
overtreatment. 
Realizing the limitations of the multivariable analysis,
and the very different clinical context of patient groups
defined as either PTLD or another iatrogenic immunodefi-
ciency EBV-LPD, the decision was made to analyze the two
groups separately (Online Supplementary Table S1); this pre-
cluded comprehensive statistical analysis and, therefore,
only descriptive statistics were used. 
The subgroup of patients with PTLD consisted of 41
hematopoietic stem cell and 21 solid organ transplant recip-
ients. The distribution of morphological subtypes was sim-
ilar in the SOT and SCT subgroups with approximately
60%-65% monomorphic disease. In those patients pre-
senting with monomorphic PTLD, 90% (35 of 39) had
been classified as monoclonal EBV-LPD. The 4 monomor-
phic PTLD cases without monoclonal IG status all had
oligoclonal EBV-LPD and displayed similar clinical features
to the monoclonal cases. Mortality was high at 36% (14 of
39) despite the use of R/R-chemo (Figure 1A) More specifi-
cally, of the 14 patients who died, 13 had monoclonal and
one oligoclonal EBV-LPD. 
In patients with reactive/polymorphic PTLD, the IG-
clonality status seemed to be of importance. Monoclonality
resulted in an unfavorable outcome with a mortality rate of
33%, which is similar to that seen in the patients with
monomorphic PTLD. However, a considerable number of
deaths were caused by insufficient treatment. Five patients
who died had not received R/R-chemo, probably as a result
of inadequate risk assessment based on morphology, age
and stage. In contrast, polyclonal reactive/polymorphic
PTLD patients had a good outcome with modification of
immunosuppression only (Figure 1A). 
There were 24 patients with another iatrogenic immun-
odeficiency EBV-LPD, which involved 22 patients treated
for inflammatory bowel disease, e.g. Crohn disease and
ulcerative colitis. Extranodal disease involving the diseased
colon itself was very common, 72% (16 of 22). Overall,
EBV-LPD mortality was 8% (2 of 24). Ann Arbor staging
seemed most predictive for outcome (Figure 1B). Stage I
disease (n=16) was effectively cured by only modifying
immunosuppressive therapy, sometimes complemented by
surgical resection; the IG clonality status (44% monoclonal)
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Figure 1. Flowcharts of the clini-
co-pathological features and
patient outcome of patients with
EBV-related lymphoproliferative
disorders and separated by diag-
nose subgroups  iatrogenic EBV-
LPD and PTLD.  The therapy that
had been applied mostly is
shown in the dark blue boxes.
The number of patients who
actually did receive rituximab
alone or in combination with
chemotherapy (R/R-chemo) are
shown in the green boxes.
Outcome is expressed as mor-
tality rate and indicated in the
red boxes. IS: immunosuppres-
sant; MC: monoclonal;  O/PC:
oligo/polyclonal.
A B
was not relevant. More advanced stages, II-IV (n=8), which
proved monoclonal in 75% of the cases, required treatment
with rituximab (R) alone or combined with chemotherapy
(R-chemo), but there was still a mortality rate of 25% (2 of
8) (Figure 1B). The 2 patients who had died both had mon-
oclonal disease and succumbed despite use of R/R-chemo.
Our analysis shows that IG-clonality status might be use-
ful in the risk stratification and therapeutic decision making
in patients with EBV-LPD in the setting of PTLD.
Monoclonal, monomorphic EBV-LPD in PTLD requires
early aggressive intervention; polyclonal reactive EBV-LPD
may be managed conservatively. In IBD patients with EBV-
LPD, low disease stage is more predictive of survival,
regardless of whether or not the disease is monoclonal. The
fast and full recovery of immunity with reduction of
immunosuppressants expected in these patients, who have
no additional immunological deficits, seems sufficient to
achieve a remission. This contrasts with the situation of
PTLD after transplantation where more profound and pro-
longed immune deficits arise from pre-treatment and con-
ditioning therapy, which precludes control of EBV-LPD by
a functional immune system on cessation of immunosup-
pressants.12,13 Reactive/polymorphic and polyclonal PTLD
probably reflects an earlier phase of the disease where there
might be more time for immune recovery to occur, and so,
even in the setting of transplantation, additional therapy
can be reserved for those failing modification of immuno-
suppressive therapy. 
Our analysis has several limitations that are related to the
retrospective nature of the study and the limited sample
size. Nevertheless, our findings appeal for future multicen-
ter prospective studies that incorporate IG-gene clonality
testing in a risk stratified approach to PTLD. 
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